Locations:
Search IconSearch
August 1, 2022/Cancer

Lung Cancer Screening Entails More Than CT Scans (Podcast)

High-quality programs help ensure that screening – now considered standard of care – is done right

In 2021, the U.S. Preventive Services Task Force expanded its eligibility for lung cancer screening to encompass adults aged 50 to 80 years old who have a 20-pack-year smoking history and currently smoke or have quit within the past 15 years. The change is science-based, taking into consideration research such as the NELSON Study that showed reduced lung cancer mortality with low-dose CT screening.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The bottom line is absolutely there’s mortality benefit from screening,” says Peter Mazzone, MD, MPH, Director of the Lung Cancer Program and Lung Cancer Screening Program in Cleveland Clinic’s Respiratory Institute. “Lung cancer screening should now be considered standard of care.”

In a featured episode of Cleveland Clinic’s Respiratory Exchange podcast, Dr. Mazzone talks about lung cancer screening, including:

  • The difference between screening and diagnostic testing.
  • Potential harms of low-dose CT scan for screening.
  • Advice for launching a lung cancer screening program.
  • The importance of generating awareness and knowledge about screening among the provider community.
  • The future of lung cancer screening, including new screening algorithms and population management systems.

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Respiratory Exchange episodes at my.clevelandclinic.org/podcasts/respiratory-exchange or wherever you get your podcasts.

Excerpt from the podcast

Podcast host Raed Dweik, MD, MBA: You’ve spent a lot of time and energy building our lung cancer screening program here. Can you share with our audience … what it takes to establish a lung cancer screening program?

Dr. Mazzone: I like the question because you use the word “program.” … Screening is not just a test here. It is a program. An what’s most important is that the programs are designed to provide really high-quality care. You’re screening the right individuals; you’re using proper imaging techniques. You’re talking to patients about the benefits and harms, letting them make informed decisions about whether to participate.

Advertisement

You have systems in place to manage the findings from the scan, whether it be the lung nodules we talked about or anything else that’s imaged on the chest. You have systems in place to help patients adhere to follow-up recommendations and to the annual scan.

In general, the design of the program only matters in that you have to meet each of those components of high-quality screening that I listed. And in general, the design can be divided into a centralized program or a decentralized program.

Centralized means a provider refers someone to the program, and the program does the rest. They talk to the patient, do the scan, interpret it and manage the findings. Decentralized would be the entire opposite. The primary provider talks to the patient, identifies the right patients, orders the test and then manages all the findings.

One system isn’t necessarily right or wrong; it depends on where you’re practicing and what your resources are. But what’s critical is that each of those components is present.

In general, in the literature, it’s been shown that a centralized program is more likely to screen the proper population; they have better adherence to follow-up recommendations and annual screening. And so we certainly favor centralized screening. But we also have to recognize that every place that has patients eligible doesn’t have the same resources to develop that.

In that situation, I’d suggest connecting or combining with larger health systems, regionally or nationally, to help make sure that you’re checking all the boxes – that you have all these components in place.

Advertisement

Related Articles

Dr. Khorana
April 25, 2025/Cancer/News & Insight
Molecular Insights into Early-Onset Biliary Tract Cancer (Podcast)

A call for awareness about the importance of genomic testing

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Ad